Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,509.00-0.03%ETH$2,664.82-1.05%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
MD

NASDAQ · MDXH

MDxHealth SA Ordinary Shares

Healthcare · Medical - Diagnostics & Research

$0.58

Down-$0.01 (-0.90%)

Updated Oct 2, 2026, 10:03 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
168.79M
P/E ratio
-5.04
Dividend yield
0.00%
52-week range
$0.40 – $3.56
Volume
117.81K
Avg. volume
210.84K

Price performance · MDXH

MDXH price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

MDXH closed at $0.58 after 20 trading sessions, down 20.66% for the selected period.

Last close
$0.58
Period change
-20.66%
Period low
$0.52
Period high
$0.75
Daily close
View OHLC price history
MDXH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$0.60$0.60$0.5596$0.5762117.81K
Sep 30, 2026$0.5201$0.6398$0.5201$0.5846451.79K
Sep 29, 2026$0.5316$0.5499$0.5185$0.52311.05K
Sep 28, 2026$0.56$0.5742$0.546$0.54895.1K
Sep 25, 2026$0.58$0.5999$0.5604$0.5652236.25K
Sep 24, 2026$0.6046$0.6046$0.5628$0.582222.72K
Sep 23, 2026$0.60$0.616$0.583$0.6055109.13K
Sep 22, 2026$0.6378$0.6378$0.5911$0.5999315.36K
Sep 21, 2026$0.63$0.65$0.595$0.60347.71K
Sep 18, 2026$0.6595$0.6815$0.62$0.63276.37K
Sep 17, 2026$0.68$0.703$0.67$0.6717258.78K
Sep 16, 2026$0.6791$0.6935$0.6606$0.6807133.96K
Sep 15, 2026$0.70$0.70$0.6701$0.6732132.43K
Sep 14, 2026$0.69$0.7392$0.6858$0.707285.6K
Sep 11, 2026$0.67$0.7147$0.66$0.7046259.06K
Sep 10, 2026$0.695$0.6995$0.667$0.676283.4K
Sep 9, 2026$0.72$0.726$0.691$0.69289.38K
Sep 8, 2026$0.7499$0.75$0.70$0.7135329.98K
Sep 4, 2026$0.719$0.7499$0.7123$0.7484271.6K
Sep 3, 2026$0.7307$0.7349$0.703$0.7262169.61K

Latest MDXH news

The latest Smart Investors Daily articles mentioning MDXH.

Stock researchCompany · Overview

MDXH research

Overview

Company profile and research snapshot.

Company profile

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
MDXH recent ratings
DateFirmRatingTarget
Aug 21, 2026BTIGBuy—
Aug 14, 2026Lake StreetBuy—
May 14, 2026Lake StreetBuy—
May 14, 2026TD CowenBuy—
May 14, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 5, 2026

MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution

MDxHealth now carries a refreshed fair value estimate of US$1.80, down from US$2.20, which marks about an 18% reduction in the central price target used in the latest analyst model. This shift reflects recent commentary that weighs progress in prostate cancer diagnostics and balance sheet clean up against dilution from new equity and questions about execution after the Resolve wind down. As you read on, you will see how these moving parts shape the evolving MDxHealth story and what to watch...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By